Tipifarnib

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HRAS Gene Mutation

Conditions

HRAS Gene Mutation, HNSCC

Trial Timeline

Mar 15, 2019 → May 2, 2023

NCT ID

NCT03719690

About Tipifarnib

Tipifarnib is a phase 2 stage product being developed by Kura Oncology for HRAS Gene Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT03719690. Target conditions include HRAS Gene Mutation, HNSCC.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04809233	Pre-clinical	Active	—	—	HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
NCT04865159	Phase 1	Terminated	May 6, 2021	May 2, 2023	Advanced Solid Tumor
NCT03719690	Phase 2	Completed	Mar 15, 2019	May 2, 2023	HRAS Gene Mutation
NCT02807272	Phase 2	Completed	Jan 10, 2017	Nov 30, 2020	Leukemia, Myelomonocytic, Chronic
NCT02779777	Phase 2	Terminated	Jun 1, 2016	Aug 28, 2018	Myelodysplastic Syndromes
NCT02464228	Phase 2	Completed	Feb 25, 2016	Mar 31, 2021	Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT02383927	Phase 2	Completed	May 13, 2015	Dec 14, 2020	Thyroid Cancer

Competing Products

2 competing products in HRAS Gene Mutation

See all competitors

Product	Company	Stage	Hype Score
Darlifarnib + Cabozantinib + Adagrasib	Kura Oncology	Phase 1	30
Tipifarnib	Kura Oncology	Pre-clinical	24